-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the results of phase 2 clinical trials of the hypoxia-inducible factor inhibitor belvutifan developed by Merck & Co.
VHL is a rare genetic disease that abnormally activates hypoxia-inducible factor (HIF-2α) in cancer patients
The results published in the "New England Journal of Medicine" showed that of the 61 patients with renal cell carcinoma treated, 30 (49%) achieved partial remission, and 30 patients (49%) had stable disease
▲Belzutifan's Phase 2 clinical trial data (picture source: reference [1])
The 61 patients who participated in the trial also had lesions in other parts of the body.
In the discussion, the researchers pointed out that the usual treatment for tumors associated with VHL disease is to use surgery to reduce the risk of metastatic disease
Note: The original text has been deleted
Reference materials:
[1] Jonasch et al.
